Сингапур - английский - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - cabozantinib (s)-malate 76.03mg eqv cabozantinib - tablet, film coated - cabozantinib (s)-malate 76.03mg eqv cabozantinib 60mg

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 25.34mg equivalent to cabozantinib 20 mg - film coated tablet - 20 mg - active: cabozantinib s-malate 25.34mg equivalent to cabozantinib 20 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 50.69mg equivalent to cabozantinib 40 mg - film coated tablet - 40 mg - active: cabozantinib s-malate 50.69mg equivalent to cabozantinib 40 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - cabozantinib s-malate 76.03mg equivalent to cabozantinib 60 mg - film coated tablet - 60 mg - active: cabozantinib s-malate 76.03mg equivalent to cabozantinib 60 mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry yellow 03k92254 - cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc): - in treatment-na?ve adults with intermediate or poor risk - in adults following prior treatment with vascular endothelial growth factor targeted therapy.

Иордания - английский - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الشرق شخشير - orient drug store co - ipilimumab 50 mg/10ml - 50 mg/10ml

Канада - английский - Health Canada

bristol-myers squibb canada - ipilimumab - solution - 5mg - ipilimumab 5mg - antineoplastic agents

Канада - английский - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 20mg - cabozantinib (cabozantinib malate) 20mg - antineoplastic agents

Канада - английский - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 40mg - cabozantinib (cabozantinib malate) 40mg - antineoplastic agents

Канада - английский - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 60mg - cabozantinib (cabozantinib malate) 60mg - antineoplastic agents

Австралия - английский - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - ipilimumab, quantity: 213 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,winglore, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,winglore, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),winglore, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),winglore, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),winglore, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),winglore in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.